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Abstract
ColonSentry® is a minimally invasive, blood-based risk 
assessment test for colorectal cancer. The test is used to 
increase patient compliance with colonoscopy. Many 
physicians have inquired about the incidence of non-
malignant lesions found in patients after colonoscopy 
prompted by an increased risk score on the ColonSentry 
test. Here we report on the colonoscopy results of five 
patients with increased ColonSentry risk scores. Of those 
five patients, three were determined to have polyps, one 
of which was pre-malignant.
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INTRODUCTION
Colorectal cancer is the world’s third most common 
cancer and the fourth most common cause of global 
cancer death[1]. Early detection of colorectal cancer 
through screening can increase 5-year survival rates to 
90% [2]. The gold standard for colorectal cancer screening 
is colonoscopy. However, this procedure is inconvenient 
and not without risks. Colonoscopy requires bowel 
preparation, and patients need to take time off work. 
Minor risks are common; approximately one-third of 
patients having colonscopy report minor gastrointestinal 
symptoms. Rare but serious complications, including 
bowel perforation, have been estimated to occur 
approximately 2.8 times per 1000 screening colonoscopy 
procedures carried out in average-risk populations[3]. 
As a result, many patients are reluctant to undergo 
colonoscopies, and screening compliance for colorectal 
cancer is less than for other malignancies such as breast 
cancer[1].
ColonSentry is a pre-screening blood-based test 
developed by GeneNews Ltd. The test is convenient and 
patient friendly, requires no bowel preparation or dietary 
restrictions and, since it is a simple blood test, carries 
minimal risks of complications. ColonSentry measures the 
gene expression profile of 7 genes. Those patients who 
present with an above-average risk score for colorectal 
cancer can then be referred for colonoscopy[4-5].
Materials & Methods
ColonSentry blood samples were collected from patients 
in Malaysia between 6 June 2011 and 29 August 2013; 
250 Malaysian patients had the ColonSentry test. 
Samples were collected using PaxGene tubes 
(PreAnalytix, Hombrechtikon, Switzerland). Whole blood 
RNA was isolated as described previously[4].  Isolated 
RNA was checked using 2100 Bioanalyzer RNA 6000 
Nano Chips (Agilent Technologies, CA). RNA quantity 
was determined by absorbance at 260nm with a NanoDrop 
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2000c UV-vis Spectrophotometer  (Thermo Scientific, 
DE).
Quantitative reverse-transcription real-time RT-PCR 
reaction procedures for the seven gene biomarkers have 
been described previously[4].  Briefly, one microgram 
of RNA was reverse transcribed into single-stranded 
complementary DNA (cDNA) using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) in 
1X RT reaction. 
For qPCR, 20 ng cDNA was mixed with Quantitect® 
Probe PCR Master Mix (Qiagen) and Taqman® dual-
labeled probe and primers corresponding to the gene of 
interest and reference gene, in a 25 µL reaction volume. 
PCR amplification was performed using a 7500 Real-
Time PCR System (Applied Biosystems). 
Sixty-seven patients who had taken the ColonSentry 
test were identified as being at or above a 2-fold 
increased risk for colorectal cancer and were referred for 
colonoscopy. These patients were asked to provide their 
colonoscopy results to us if they were going to have a 
colonoscopy after our ColonSentry test. 
RESULTS
From 6 June 2011 to 29 August 2013, 250 Malaysian 
patients took a ColonSentry blood test. Sixty-seven of 
those patients were identified as being at or above a 2-fold 
increased risk for colorectal cancer and were referred for 
colonoscopy.
Patient Follow-Up and Colonoscopy Results
By 01 September 2013, 5 of the patients had submitted 
their colonoscopy results to us (Table 1).  
Table 1
Colonoscopy and ColonSentry® Test Results for the Five Patients Who Have Submitted Their Colonoscopy 
Results
Patient ID Gender Age ColonSentry®risk score Colonoscopy & pathology results
GND100343 M 73 + 7.7X Two sessile polyps not sentto pathology
GND100345 F 64 > + 10.0X Normal colonoscopy
GND100053 F 53 + 8.4X Benign hyperplastic polyp
GND100055 M 56 + 7.7X Normal colonoscopy
GND100220 M 42 + 4.2X
Four polyps:
1 moderately atypical tubular  adenoma
3 benign polyps
Discussion
Of the 67 high risk patients referred for colonoscopy, 
5 patients submitted their colonoscopy results to us for 
analysis. Sixty-two patients did not submit their results 
(if any) to us. Of the 5 patients, 3 were found to have 
polyps, including 1 patient who had a premalignant, 
moderately atypical tubular adenoma (Figure 1). 
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Figure 1
Patient GND100220: Colonoscopy report and images
These findings indicate that the ColonSentry test can 
predict the presence of non-malignant colorectal lesions 
as well as the presence of colorectal cancer. Currently, 
only a few results have been made available to us, as only 
five patients have given us their colonoscopy results. The 
remaining 62  patients with an increased-risk score have 
not provided us with their colonoscopy  results. As more 
increased-risk patients submit their colonoscopy results to 
us, we expect to extend these preliminary findings.
In a previous paper published in 2010 we identified 
the 7-gene biomarker panel, which forms the basis 
of the ColonSentry test,  and we discuss these genes 
in that report (4). These biomarkers are probably not 
conventional cancer biomarkers but rather are subtle, 
systemic alterations in blood gene expression in response 
to disease.
CONCLUSION
Based on the above preliminary findings, the ColonSentry 
test may be able to predict the presence of polyps, 
including pre-malignant polyps. This should provide a 
Pathology Observation
Polyp 1. Mucous of ileum. No atypism in glandular 
epithelium. At mesenchyma, assembly of lymphoid 
follicles-like cells. Infiltrated lymph showed no 
atypism.
Polyp 2. In the mucous, proliferation of moderate 
atypical tubular adenoma (premalignantpolyp) could 
be observed. 
Polyps  3 and 4.  Extensive formation of polyps.
further impetus for patients with an elevated risk score on 
the ColonSentry test to proceed to colonoscopy.
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